FDA's Top Regulator Influences Replimune's Cancer Therapy Rejection
TL;DR Summary
The FDA's top cancer drug regulator, Richard Pazdur, played a key role in the rejection of Replimune's skin cancer therapy, RP1, amid internal agency dysfunction and leadership changes, despite support from other officials. The decision was influenced by internal debates and procedural issues within the FDA.
- FDA’s top cancer drug regulator played key role in rejection of Replimune therapy, officials say statnews.com
- The story behind the Replimune rejection, and San Diego sees a biotech winter statnews.com
- Replimune stock down after report on drug rejection (REPL) Seeking Alpha
- Navigating the Fallout: Replimune's FDA Hurdle and the Road to Investor Recovery AInvest
- FDA Rejects Replimune’s Skin Cancer Therapy Following Input from Top Oncology Drug Regulator geneonline.com
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
1 min
vs 2 min read
Condensed
85%
307 → 46 words
Want the full story? Read the original article
Read on statnews.com